<DOC>
	<DOCNO>NCT01130142</DOCNO>
	<brief_summary>Study IPI-926-03 Phase 1b/2 clinical trial evaluate IPI 926 combination gemcitabine patient previously untreated metastatic pancreatic cancer . Phase 1b design dose escalation study . Once maximum tolerate dose IPI-926 combination gemcitabine establish Phase 1b portion study , Phase 2 portion commence . Phase 2 design randomize , double-blind ( investigator/patient ) , placebo-controlled study . There cross-over option patient either arm Phase 2 ( i.e. , option patient receive placebo cross-over IPI-926 ) .</brief_summary>
	<brief_title>A Study Evaluating IPI-926 Combination With Gemcitabine Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>IPI 926 inhibitor Hedgehog Pathway . IPI-926 combination gemcitabine may improve therapeutic outcome patient pancreatic cancer . Infinity conduct Phase 1b/2 clinical trial evaluate safety efficacy IPI-926 combination gemcitabine patient previously untreated metastatic pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veratrum Alkaloids</mesh_term>
	<criteria>18 year age Pathologically confirm metastatic pancreatic adenocarcinoma At least 1 radiologically evaluable metastatic lesion ( RECIST 1.1 ) . ECOG 0 1 Life expectancy â‰¥3 month . All woman child bear potential , sexually active male patient , partner patient must agree use adequate method birth control Ability adhere study visit schedule Voluntarily sign informed consent form Islet cell , acinar cell carcinoma , nonadenocarcinoma , ( i.e. , lymphoma , sarcoma ) , adenocarcinoma originate biliary tree cystadenocarcinoma Prior treatment chemotherapy pancreatic cancer . Known central nervous system metastasis Inadequate hematologic function Inadequate hepatic function Inadequate renal function External ( percutaneous ) biliary drain History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month . Venous thromboembolic event ( e.g. , pulmonary embolism deep vein thrombosis ) require anticoagulation appropriately anticoagulated NCI CTCAE Grade 2 great bleeding episode 3 week prior administration IPI926 Concurrent administration medication food know inhibit CYP3A activity clinically relevant degree Presence active infection systemic use antibiotic within 72 hour treatment Significant comorbid condition disease judgment Investigator would place patient undue risk interfere study . Known human immunodeficiency virus ( HIV ) positivity Known hypersensitivity gemcitabine , IPI926 , excipients Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>